These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29537654)

  • 41. Are targeted HIV prevention activities cost-effective in high prevalence settings? Results from a sexually transmitted infection treatment project for sex workers in Johannesburg, South Africa.
    Vickerman P; Terris-Prestholt F; Delany S; Kumaranayake L; Rees H; Watts C
    Sex Transm Dis; 2006 Oct; 33(10 Suppl):S122-32. PubMed ID: 16735954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Current status of the female condom in Africa].
    Deniaud F
    Sante; 1997; 7(6):405-15. PubMed ID: 9503499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implants for HIV prevention in young women: Provider perceptions and lessons learned from contraceptive implant provision.
    Humphries H; Upfold M; Mahlase G; Mdladla M; Gengiah TN; Abdool Karim Q
    PLoS One; 2022; 17(1):e0262043. PubMed ID: 35025908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
    Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
    AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa.
    Minnis AM; Krogstad E; Shapley-Quinn MK; Agot K; Ahmed K; Danielle Wagner L; van der Straten A;
    Sex Reprod Health Matters; 2021 Dec; 29(1):1927477. PubMed ID: 34224341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers.
    Mukandavire Z; Mitchell KM; Vickerman P
    Epidemics; 2016 Mar; 14():62-70. PubMed ID: 26972515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.
    Pretorius C; Stover J; Bollinger L; Bacaër N; Williams B
    PLoS One; 2010 Nov; 5(11):e13646. PubMed ID: 21079767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perception of couples' on multipurpose prevention technology attribute choice: the case of MTN 045.
    Dandadzi A; Young AM; Musara P; Shapley-Quinn MK; Kemigisha D; Mutero P; Mgodi NM; Etima J; Minnis AA
    BMC Public Health; 2024 Jul; 24(1):1876. PubMed ID: 39004714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa.
    Dietrich JJ; Atujuna M; Tshabalala G; Hornschuh S; Mulaudzi M; Koh M; Ahmed N; Muhumuza R; Ssemata AS; Otwombe K; Bekker LG; Seeley J; Martinson NA; Terris-Prestholt F; Fox J
    BMC Health Serv Res; 2021 Jan; 21(1):17. PubMed ID: 33407395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa: a health economic and modelling analysis.
    Cambiano V; Johnson CC; Hatzold K; Terris-Prestholt F; Maheswaran H; Thirumurthy H; Figueroa C; Cowan FM; Sibanda EL; Ncube G; Revill P; Baggaley RC; Corbett EL; Phillips A;
    J Int AIDS Soc; 2019 Mar; 22 Suppl 1(Suppl Suppl 1):e25243. PubMed ID: 30907498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study.
    Grant H; Mukandavire Z; Eakle R; Prudden H; B Gomez G; Rees H; Watts C
    J Int AIDS Soc; 2017 Sep; 20(1):21744. PubMed ID: 28953330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision.
    Mudimu E; Peebles K; Mukandavire Z; Nightingale E; Sharma M; Medley GF; Klein DJ; Kripke K; Bershteyn A
    PLoS One; 2020; 15(12):e0244761. PubMed ID: 33382803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
    Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
    PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA.
    Verguet S; Walsh JA
    Sex Transm Infect; 2010 Jun; 86(3):212-6. PubMed ID: 20522634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An individually randomized controlled trial of a mother-daughter HIV/STI prevention program for adolescent girls and young women in South Africa: IMARA-SA study protocol.
    Donenberg GR; Atujuna M; Merrill KG; Emerson E; Ndwayana S; Blachman-Demner D; Bekker LG
    BMC Public Health; 2021 Sep; 21(1):1708. PubMed ID: 34544403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
    Ngure K; Friedland BA; Szydlo DW; Roberts ST; Garcia M; Levy L; Akello CA; Reddy K; Palanee-Phillips T; Macdonald P; Siziba B; Soto-Torres L; Hosek S; Hillier SL; Nair G; Celum C; van der Straten A
    PLoS One; 2023; 18(6):e0287525. PubMed ID: 37352296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.